DUL:ETR
Alnylam Pharmaceuticals, Inc.
€205.50
arrow_downward
-0.48%(-1.00) 1D
Oct 12, 5:35:58 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
€209.10
High
€209.10
Low
€205.50
Mkt. cap
30.38B
Avg. vol.
40.00
Volume
10.00
52-wk high
€417.40
52-wk low
€177.10
No. of employees
2K
Open
€209.10
High
€209.10
Low
€205.50
Mkt. cap
30.38B
Avg. vol.
40.00
Volume
10.00
52-wk high
€417.40
52-wk low
€177.10
No. of employees
2K
News stories
From web sources and news partners
The Globe and Mail
·
2 hours ago
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Solventum Corporation (SOLV)
Investing.com
·
1 day ago
Alnylam EVP Bryan Supran sells $398,855 in shares
Investing.com Nigeria
·
1 day ago
Form 4 Alnylam Pharmaceuticals Inc For: 11 October By Investing.com
Simply Wall Street
·
1 day ago
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.